Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, summarized key highlights from its Investor Event held on November 9. An archive of the presentation webcast is available through the Investor Relations section of Geron's website under Events. The Company also reported its financial results for the third quarter and year to date 2021 periods.

Geron Presents Investor Event Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that three abstracts related to imetelstat, the Company's first-in-class telomerase inhibitor, have been accepted as poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021. The abstracts are available on the ASH

Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting

Clear Channel Outdoor Holdings

Check-Cap

Calyxt

KULR Technology Group

Some of the best penny stocks 2021 has offered were some of… The post 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175%

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for

Ebang International Holdings

China Rapid Finance

Which penny stocks are on your November 2021 watchlist? The post 3 Hot Penny Stocks to Watch in November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Watch in November 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that imetelstat, the Company's first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway (ILAP) launched in the United Kingdom (UK) by the Medicines and Healthcare produc

Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat

Geron has seen some favorable Phase II data from their core product pipeline, which helped drive their share price up by ~20% over the past few months.

Geron: Still A Strong Buy After New Phase II Data And 20% Return

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). Based upon current planning assumptions, Geron expects top-line results for IMerge Phase 3 to b

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Host a Virtual Investor Event in November

Geron to Host a Virtual Investor Event in November

The stock price of Geron Corporation (Nasdaq: GERN) increased by over 7% during intraday trading today. This is why it happened.

GERN Stock: Why It Increased Today

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: H.C. Wainwright 23rd Annual Global Virtual Investment Conference on Monday, September 13, 2021 at 7:00 a.m. ET. R.W. Baird 2021 Virtual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET. 2021 Cantor Virtual Global Healthcare Conference on Thursday,

Geron Announces September Investor Conference Presentation Webcasts

It could be a while before Geron has a big catalyst.

Here's What Investors Need From Geron

Geron's main product pipeline is a therapeutic in the cancer treatment market which showed promise but not great potential. Given expectations for the product, if approved, relative to current market sentiment, I believe mind-bending returns of over 1,000% are possible and worth the risk of a small position.

Geron: Potential For Mind-Bending Returns With Current Pipeline

Geron Corporation (GERN) CEO Dr. John Scarlett on Q2 2021 Results - Earnings Call Transcript

Shares of Geron (NASDAQ:GERN) rose 2.5% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 50.00% over the past year to ($0.09), which missed the estimate of ($0.08).

Recap: Geron Q2 Earnings

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financial results for the second quarter ended June 30, 2021. The Company will host a conference call today at 4:30 p.m. ET to discuss these updates and current events. As of June 30, 2021, the Company had $239.1 million in cash and marketable securities. These financial resources, combined with expected

Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021

Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021

Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Geron (GERN) Stock We Don't?

Geron published data from its MF study in the Journal of Clinical Oncology.

Geron: End Of The Tunnel

Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Clinical Oncology. The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as positive biomarker and bone marrow fibrosis assessments, in heavily pre-treated patients.

Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication In Journal

The stock price of Geron Corporation (NASDAQ: GERN) increased by over 30% pre-market. This is why it happened.

GERN Stock Price Increases Over 30% Pre-Market: Why It Happened

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.” The publication highlights the clinical benefits observed in the study, including symptom response and overall survival

News for Geron Stock (GERN)